Kalvista Pharmaceuticals Inc (KALV)

$10.72 0.23 (2.19%)

12:11 EDT KALV Stock Quote Delayed 30 Minutes

KALV Stock Earnings: KalVista Pharma Misses EPS for Q2 2024

By InvestorPlace Earnings Dec 7, 2023

KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the second quarter of 2024.

3 Micro-Cap Stocks That Could Be Moonshots

Why Is KalVista Pharmaceuticals (KALV) Stock Down 50% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

More Articles

Volume:

Previous Close -

Market Cap 366.98M

PE Ratio -7.15

EPS -1.5

Volume (Avg. Vol.) 66,739

Day's Range $10.26 - $10.72

52-Week Range $7.21 - $16.88

Dividend & Yield N/A (N/A)

KALV Stock Predictions, Articles, and Kalvista Pharmaceuticals Inc News

From InvestorPlace
From the Web

KALV Stock: 8 Things to Know About KalVista Pharmaceuticals as Shares Skyrocket Today

By Nick Clarkson, Web Editor Feb 9, 2021

Shares of KALV stock are blasting off on Tuesday after KalVista Pharmaceuticals reported strong results from its HAE treatment clinical trial.

5 Stocks to Buy Based on Insider Buying

By Mark Putrino, CMT Oct 8, 2019

These are five stocks to consider buying because of significant insider buying activity. Insiders only buy for one reason: to make money.

KalVista Pharmaceuticals CFO discloses sale of 40,855 shares (NASDAQ:KALV)

From Seeking Alpha Feb 16, 2024

The CFO of KalVista Pharmaceuticals sold 40,855 shares for $613,205. There have been a total of 37 insider trades in the last three months.

KalVista Pharmaceuticals up 16%, prices $160M offering (NASDAQ:KALV)

From Seeking Alpha Feb 15, 2024

KalVista Pharmaceuticals (KALV) priced an underwritten public offering of ~7M shares at a price to the public of $15.25 per share and pre-funded warrants to pur

KalVista announces proposed public offering of stock and pre-funded warrants (NASDAQ:KALV)

From Seeking Alpha Feb 14, 2024

KalVista Pharmaceuticals (NASDAQ:KALV) intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of common stock in...

Two Biotech/pharma stocks to watch - STTK, KALV

From Seeking Alpha Feb 14, 2024

Despite positive tidings, shares of Shattuck Labs (STTK) and KalVista Pharmaceuticals (KALV) closed lower Tuesday. Is this a buy-the-dip opportunity?

KalVista stock jumps after trial success (NASDAQ:KALV)

From Seeking Alpha Feb 13, 2024

KalVista Pharmaceuticals (KALV) stock rose as its oral therapy for hereditary angioedema, sebetralstat, reached its goals in a Phase 3 trial. Read more here.

Analysts Are Bullish on These Healthcare Stocks: Marinus (MRNS), KalVista Pharmaceuticals (KALV)

From TipRanks Dec 9, 2022

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Marinus (MRNS – Research Report), KalVista Pharmaceu...

ADVERTISEMENT